Skip to Content

Subcutaneous Daratumumab in Multiple Myeloma shows reduced the risk of progression or death by 37%

Get an overview of the results from the phase 3 study, APOLLO, presented by Dr. Dimopoulos at ASH. New treatment for patients with refractory multiple myeloma.

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top